At the news
? BULLISHIMPACT 6/10 COURT-RULING filed Apr 12, 2026 at 20:00 ET
The District Court of New Jersey adopted a Special Master's Report and Recommendation, partially granting Teva's motion to dismiss Mylan's antitrust lawsuit over Copaxone. The court dismissed with prejudice several key allegations, including claims related to citizen petitions, ANDA litigation, market shift, and copay assistance, while allowing the DAW campaign, exclusionary PBM agreements, and the 2020 reclassification petition/lawsuit to proceed. This significantly narrows the scope of the litigation and reduces Teva's potential antitrust exposure.
- Court dismissed with prejudice allegations about 20mg citizen petitions, 20mg ANDA lawsuit, 2014 FDA lawsuit, 40mg ANDA lawsuit, non-Orange Book patent litigation, market shift, and copay assistance.
- Court struck foreign allegations from the complaint.
- Surviving claims: DAW campaign (false statements to doctors), exclusionary agreements with PBMs, and the 2020 reclassification petition/lawsuit.
- Lanham Act claim (Count II) and state law claims (Counts III-VI) also survive.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access